Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer With Brain Metastases
NCT07745257Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib, anlotinib in breast cancer, sponsored by Sun Yat-sen University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
culmerciclibanlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07745257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745257.